Cover Image

Time to disability milestones and annualized relapse rates in NMOSD and MOGAD

Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relat...

Full description

Saved in:
Bibliographic Details
Main Authors: Duchow, Ankelien (Author) , Bellmann-Strobl, Judith (Author) , Friede, Tim (Author) , Aktas, Orhan (Author) , Angstwurm, Klemens (Author) , Ayzenberg, Ilya (Author) , Berthele, Achim (Author) , Dawin, Eva (Author) , Engels, Daniel (Author) , Fischer, Katinka (Author) , Flaskamp, Martina (Author) , Giglhuber, Katrin (Author) , Grothe, Matthias (Author) , Havla, Joachim (Author) , Hümmert, Martin W. (Author) , Jarius, Sven (Author) , Kaste, Matthias (Author) , Kern, Peter (Author) , Kleiter, Ingo (Author) , Klotz, Luisa (Author) , Korporal-Kuhnke, Mirjam (Author) , Kraemer, Markus (Author) , Krumbholz, Markus (Author) , Kümpfel, Tania (Author) , Lohmann, Lisa (Author) , Ringelstein, Marius (Author) , Rommer, Paulus (Author) , Schindler, Patrick (Author) , Schubert, Charlotte (Author) , Schwake, Carolin (Author) , Senel, Makbule (Author) , Then Bergh, Florian (Author) , Tkachenko, Daria (Author) , Tumani, Hayrettin (Author) , Trebst, Corinna (Author) , Vardakas, Ioannis (Author) , Walter, Annette (Author) , Warnke, Clemens (Author) , Weber, Martin S. (Author) , Wickel, Jonathan (Author) , Wildemann, Brigitte (Author) , Winkelmann, Alexander (Author) , Paul, Friedemann (Author) , Stellmann, Jan-Patrick (Author) , Häußler, Vivien (Author)
Format: Article (Journal)
Language:English
Published: Apr 2024
In: Annals of neurology
Year: 2024, Volume: 95, Issue: 4, Pages: 720-732
ISSN:1531-8249
DOI:10.1002/ana.26858
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ana.26858
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.26858
Get full text
Author Notes:Ankelien Duchow, Judith Bellmann-Strobl, Tim Friede, Orhan Aktas, Klemens Angstwurm, Ilya Ayzenberg, Achim Berthele, Eva Dawin, Daniel Engels, Katinka Fischer, Martina Flaskamp, Katrin Giglhuber, Matthias Grothe, Joachim Havla, Martin W. Hümmert, Sven Jarius, Matthias Kaste, Peter Kern, Ingo Kleiter, Luisa Klotz, Mirjam Korporal-Kuhnke, Markus Kraemer, Markus Krumbholz, Tania Kümpfel, Lisa Lohmann, Marius Ringelstein, Paulus Rommer, Patrick Schindler, Charlotte Schubert, Carolin Schwake, Makbule Senel, Florian Then Bergh, Daria Tkachenko, Hayrettin Tumani, Corinna Trebst, Ioannis Vardakas, Annette Walter, Clemens Warnke, Martin S. Weber, Jonathan Wickel, Brigitte Wildemann, Alexander Winkelmann, Friedemann Paul, Jan-Patrick Stellmann, and Vivien Häußler, on behalf of the Neuromyelitis Optica Study Group (NEMOS)
Description
Summary:Objective To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age. Methods We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS). Results We included 483 patients: 298 AQP4-IgG+ NMOSD, 52 AQP4-IgG−/MOG-IgG− NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG−/MOG-IgG− NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG+ NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time. Interpretation AQP4-IgG+ NMOSD, AQP4-IgG−/MOG-IgG− NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD.
Item Description:Vorab veröffentlicht: 12. Dezember 2023
Gesehen am 14.05.2024
Physical Description:Online Resource
ISSN:1531-8249
DOI:10.1002/ana.26858

Similar Items